(Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to
|
|
- Eugene Griffin
- 5 years ago
- Views:
Transcription
1 The Role of Human Papillomavirus Type 16/18 Genotyping in Predicting High-Grade Cervical/Vaginal Intraepithelial Neoplasm in Women With Mildly Abnormal Papanicolaou Results Ming Guo, MD 1 ; Yun Gong, MD 1 ; Jianping Wang, CT 1 ; Marilyn Dawlett, CT 1 ; Shobha Patel, CT 1 ; Ping Liu, MS 2 ; Therese B. Bevers, MD 3 ; and Nour Sneige, MD 1 BACKGROUND: The authors compared the predictive value of type 16 and/or 18 human papillomavirus (HPV) versus non-16/18 HPV types for high-grade (grade 2) cervical neoplasm/vaginal intraepithelial neoplasm and carcinoma (CIN/VAIN2þ) in women with mildly abnormal Papanicolaou (Pap) results (ie, atypical squamous cells of undetermined significance [ASCUS] or low-grade squamous epithelial lesion [LSIL]). METHODS: The authors retrospectively selected Pap specimens with HPV testing results obtained from 243 women (155 with ASCUS and 88 with LSIL Pap results) in their Department of Pathology. HPV genotyping was performed using the EasyChip HPV blot assay. The Pap specimens with HPV16/18 and non-16/18 HPV types were compared with follow-up biopsy results. Follow-up duration ranged from 1 month to 58 months (mean, 26 months). RESULTS: In total, 58 of 155 specimens (37%) that had ASCUS and 29 of 88 specimens (33%) that had LSIL were positive for HPV16/18. CIN/VAIN2þ biopsies were identified in 43 of 155 women (28%) with ASCUS and in 28 of 88 women (32%) with LSIL. Women with ASCUS and HPV16/18 had a significantly higher rate (43%) of CIN/VAIN2þ than women with ASCUS and non-16/18 HPV types (19%; P ¼.003; odds ratio, 3.10; 95% confidence interval, ). There was no statistically significant difference in the rate of CIN/VAIN2þ between women who had LSIL and HPV16/18 (45%) and those who had LSIL and non-16/18 HPV types (29%; P ¼.16; odds ratio, 1.96; 95% confidence interval, ). CONCLUSIONS: HPV genotyping for HPV16/18 improved risk assessment for women with ASCUS Pap results and may be used to predict the risk of CIN/VAIN2þ to better guide follow-up management. Cancer (Cancer Cytopathol) 2013;121: VC 2012 American Cancer Society. KEY WORDS: human papillomavirus, HPV16/18, atypical squamous cells of undetermined significance, low-grade squamous intraepithelial lesion, high-grade cervical/vaginal intraepithelial neoplasm and carcinoma. INTRODUCTION High-risk human papillomavirus (HPV) is responsible for the development of >99% of cervical carcinomas. 1 Currently, HPV DNA testing is used as a triage tool for women who have mildly abnormal Papanicolaou (Pap) results, ie, abnormal squamous cells of undetermined significance (ASCUS). According to Corresponding author: Ming Guo, MD, Department of Pathology, Unit 58, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX ; Fax: (713) ; mguo@mdanderson.org 1 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas; 3 Cancer Prevention Center, The University of Texas MD Anderson Cancer Center, Houston, Texas. Presented in part at the 59th Annual Scientific Meeting of the American Society of Cytopathology; November 4-8, 2011; Baltimore, MD. We thank the American Society of Cytopathology for Cervical Cytology and the Human Papillomavirus (HPV) Partnership Investigator Award (American Society of Cytopathology, ) and King Car Yuanshan Institute for providing reagents for the EasyChip HPV genotyping assay for the study. We also thank Ms. Jie Feng, Department of Pathology, for performing HPV genotyping tests and Mr. Walter Pagel, Scientific Publications, The University of Texas MD Anderson Cancer Center for editing the article. Received: July 9, 2012; Revised: August 21, 2012; Accepted: August 27, 2012 Published online December 5, 2012 in Wiley Online Library (wileyonlinelibrary.com) DOI: /cncy.21240, wileyonlinelibrary.com Cancer Cytopathology February
2 American Society of Colposcopy and Cervical Pathology guidelines, reflex HPV DNA testing is a preferred option for the triage of women with ASCUS Pap results. 2 Women who have positive HPV test results should be referred for colposcopy evaluation. To maximize the clinical sensitivity for high-grade (grade 2) cervical neoplasm/vaginal intraepithelial neoplasm and carcinoma (CIN/VAIN2þ), the current HPV triage strategy is to collectively test 13 or14 high-risk HPV genotypes, including HPV16 and HPV18. The US Food and Drug Administration (FDA)-approved HPV testing assays, such as Hybrid Capture 2 (HC2) (Qiagen, Valencia, Calif) and Cervista HPV HR (Hologic, Marlborough, Mass), have been used for this purpose. It has been well documented that women who have positive results for HPV types 16 and/or 18 (HPV16/18- positive results) have a significantly greater risk of developing cervical cancer than those who have other high-risk HPV types. 3-7 Women with ASCUS Pap results and HPV16-positive results had a higher cumulative 2-year risk of developing grade 2 cervical intraepithelial neoplasm (CIN2þ) than women who had other high-risk HPV genotypes. 8 Therefore, genotyping for HPV16/18 may provide valuable risk assessment that may be used in patient follow-up and management. The current HPV triage strategy, which uses 13 or 14 pooled HPV genotypes, does not allow the detection of infection with specific HPV types and, thus, cannot be used to distinguish between women who have a significantly greater risk of developing CIN/VAIN2þ and those who have a relatively lower risk. Consequently, women who have a greater risk of CIN/VAIN2þ such as HPV16/18 infections, may be lost during follow-up because of low compliance in some patients. Conversely, women who have an average risk of CIN/VAIN2þ such as non-hpv16/18 infection, may be subjected to frequently unnecessary follow-up and biopsy. Currently, the recommendation for clinical application of HPV16/18 genotyping is limited to women who have Pap-negative/HPV-positive test results for risk assessment. 2 Recently, FDA-approved commercial HPV genotyping assays for detecting HPV16/18 in Pap specimens became available for this purpose. However, HPV16/18 genotyping has not been recommended for women who have ASCUS results for risk assessment, because there is limited clinical evidence indicating that HPV16/18 test information can improve risk assessment in these patients. To evaluate the risks of CIN/VAIN2þ between HPV16/18 and non-16/18 HPV types among women with mildly abnormal Pap results, we conducted a retrospective study to compare HPV genotypes and follow-up biopsies in women who had ASCUS or low-grade squamous epithelial lesion (LSIL) Pap results. MATERIALS AND METHODS Patients and Papanicolaou Specimen Collection We retrospectively collected residual SurePath Pap specimens (BD Diagnostics, TriPath Imaging, Burlington, NC) obtained from 364 women after routine Pap testing between 2004 and 2009 in the Department of Pathology at The University of Texas MD Anderson Cancer Center. Of these, 252 women had ASCUS Pap results, and 112 had LSIL Pap results. All women underwent Hybrid Capture II (HC2) HPV DNA tests at the time of Pap cytology testing. The women ranged in age from 17 years to 90 years, and their mean age was 44 years. There were 155 Caucasian women, 39 Hispanic women, 37 African American women, 5 Asian women, and 1 woman of unknown ethnicity. The SurePath Pap specimens were screened by cytotechnologists and were verified by cytopathologists according to The Bethesda System. 9 Reflex HPV DNA tests were performed using the HC2 assay for collective testing for 13 high-risk HPV DNA types. Upon completion of the cytology diagnostic evaluation, residual material from SurePath Pap specimens was collected and stored at 80 C, as described previously. 10 The follow-up biopsies were processed and interpreted in the Department of Pathology at The University of Texas MD Anderson Cancer Center. Human Papillomavirus Genotyping With the EasyChip Human Papillomavirus Blot For HPV genotyping, DNA was extracted from the stored SurePath Pap specimens using the DNeasy kit (catalog no ; Qiagen) according to the manufacturer s instructions. HPV genotyping was conducted using the EasyChip HPV Blot (King Car Yuanshan Research Institute, I-Lan, Taiwan) as described previously. 11 The EasyChip HPV blot was designed to detect 38 HPV types (HPV types 6, 11, 16, 18, 26, 31, 32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 80 Cancer Cytopathology February 2013
3 HPV16/18 in ASCUS and LSIL/Guo et al 71,72, 74, 81, 82, 83, 84, and 85 as well as 3 intrinsic controls). First, HPV DNA was amplified with a polymerase chain reaction (PCR) assay using modified MY11/GP6- positive, biotinylated consensus primer sets to amplify a fragment of 192 base pairs in the L1 open reading frame of HPV; and forward and reverse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) biotinylated primer sets were used to amplify a 136-base pair segment for specimen validation, as described previously. 11 Briefly, PCR for HPV DNA was performed in a final reaction volume of 26 ll with a 20-ng aliquot of genomic DNA in a PCR master mixture containing 15 mm Tris-HCl, ph 8.0; 2.0 mm MgCl 2 ; 50 mm KCl; a 0.25-mM concentration of each deoxynucleotide triphosphate; 0.6 lm primer; and 0.5 U DNA polymerase (HP High Performance HotStart Taq DNA Polymerase; DNA Technologies Ltd., Cannock, United Kingdom). The PCR assay was performed as follows: 10 minutes at 95 C was followed by 40 cycles for 30 seconds at 95 C, 30 seconds at 45 C, and 30 seconds at 72 C; and a final extension for 5 minutes at 72 C. PCR for GAPDH was performed in a final reaction volume of 25 ll with a 10-ng aliquot of genomic DNA in a PCR master mixture containing 15 mm Tris-HCl, ph 8.0; 2.5 mm MgCl 2 ; 50 mm KCl; 0.2 mm of each deoxynucleotide triphosphate; 0.2 lm primer; and 0.5 U HotStart Taq DNA polymerase (DNA Technologies Ltd.). The PCR assay was performed as follows: 10 minutes at 95 Cwas followed by 40 cycles for 15 seconds at 95 C, for 1 minute at 57 C, and for 30 seconds at 72 C; and a final extension for 5 minutes at 72 C. A 5-lL aliquot of PCR products was analyzed by electrophoresis on a 2% agarose gel and stained with ethidium bromide. The hybridization was performed according to the manufacturer s instructions. The HPV types were determined by visual assessment protocol provided by King Car Yuanshan Research Institute. Patient Follow-Up The patients underwent follow-up biopsy and had a mean total follow-up of 26 months (range, 1-58 months). The majority of women (93%) underwent follow-up biopsies within 6 month of Pap/HPV testing. Case Exclusion Of the 364 women who initially were included in the study cohort, 121 women were excluded from data analysis. These included women in the following categories: 1) 34 women (9.3%) with Pap specimens that had negative HC2 results and negative EasyChip results; 2) 28 women (7.7%) with positive HC2 results but negative results for HPV DNA with the EasyChip HPV assay (no valid internal control signals were present in the specimens using the EasyChip assay, indicating insufficient DNA contents); and 3) 59 women (16.2%) who did not have follow-up biopsies. Data Analysis and Statistics Descriptive statistics were summarized for patient demographics. The chi-square test was used to test the association between 2 categorical variables. To evaluate the correlation between the incidence of CIN/VAIN2þ and HPV16/18 status, a multivariate logistic regression model was used. Two-sided P values <.05 were considered significant. All computations were carried out using the SAS statistical software package (version 8.0; SAS Institute, Cary, NC). RESULTS Distribution of Human Papillomavirus Type 16/18 and Non-16/18 Human Papillomavirus Types In total, 243 cases were validated for data analysis. These included 155 specimens with ASCUS Pap results and 88 specimens with LSIL Pap results. In specimens that had ASCUS results, HPV16/18 types were positive in 37% (58 of 155 specimens); non-16/18, high-risk HPV types (HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) were positive in 48% (74 of 155 of specimens); and other types were positive in 15% (23 of 155 specimens). In specimens that had LSIL results, HPV16/18 types were positive in 33% (29 of 88 specimens); non-16/18, highrisk HPV types were positive in 50% (44 of 88 specimens); and other types were positive in 17% (15 of 88 specimens) (Table 1). Of all 87 specimens that had positive HPV16/18 results, HPV16 was detected in 59 specimens (68%), and HPV18 was detected in 24 specimens (27%); the remaining 4 specimens (5%) were positive for both HPV16 and HPV18. Of 155 women in the ASCUS group, a single non-16/18, high-risk HPV type was detected in 56 women (36%). Multiple non-16/18, highrisk HPV types were detected in 18 women (12%). Of 88 Cancer Cytopathology February
4 TABLE 1. Distribution of Human Papillomavirus Genotypes in Women With Mildly Abnormal Papanicolaou Results No. (%) HPV Genotype ASCUS LSIL HPV16/18 58 (37) 29 (33) Non-16/18 high-risk HPV 74 (48) 44 (50) Non-high risk HPV 23 (15) 15 (17) Total Abbreviations: ASCUS, atypical squamous cells of undetermined significance; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial lesion. women in the LSIL group, a single non-16/18, high-risk HPV type was detected in 29 women (33%). Multiple non-16/18, high-risk HPV types were detected in 15 women (17%). Follow-Up Biopsies in Women With Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion Papanicolaou Results During follow-up, CIN/VAIN2þ was diagnosed in 43 of 155 women with ASCUS/HC2-positive results (28%) and in 28 of 88 women with LSIL/HC2-positive results (32%) (Table 2). Of 43 women who had ASCUS Pap results, the follow-up biopsies indicating CIN2/VAIN2þ were performed within 6 months in 34 (79%) patients and after 6 months in 9 (21%) patients. Seven patients had residual or recurrent CIN/VAIN2þ (patients with biopsies showing CIN/VAIN2þ during follow-up and rebiopsies showing CIN/VAIN2þ after treatment). Of the 28 women with LSIL Pap results, the follow-up biopsies showing CIN/VAIN2þ were obtained within 6 months in 20 women (71%) and after 6 months in 8 women (29%). Three women had residual or recurrent CIN/VAIN2þ. Comparison of Follow-Up Biopsy Results With Human Papillomavirus Type 16/18 Versus Non-16/18 Human Papillomavirus Types in Women With Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion In the ASCUS group, 25 of 58 women (43%) with HPV16/18 underwent a follow-up biopsy that indicated CIN/VAIN2þ, whereas 18 of 97 women (19%) with TABLE 2. Follow-Up Biopsies in Women With Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion Papanicolaou Results Biopsy No. With ASCUS No. With LSIL CIN CIN3/CIS 17 6 VAIN2/3 4 2 Carcinoma 5 0 CIN2 or CIN3þ/Total 43/155 (28%) 28/88 (32%) Abbreviations: ASCUS, atypical squamous cells of undetermined significance; CIN, cervical intraepithelial neoplasm; CIS, carcinoma in situ; LSIL, low-grade squamous intraepithelial lesion; VAIN, vaginal intraepithelial neoplasm. TABLE 3. Human Papillomavirus Genotypes and Follow-Up Biopsies in Women With Atypical Squamous Cells of Undetermined Significance HPV Type No./Total With CIN/VAIN21 (%) P OR 95% CI HPV16/18 25/58 (43) Non-16/18 HPV 18/97 (19) 1.00 Abbreviations: CI, confidence interval; CIN/VAIN2þ, high-grade (grade >2) cervical neoplasm/vaginal intraepithelial neoplasm and carcinoma; HPV, human papillomavirus; OR, odds ratio. non-16/18 HPV types underwent a follow-up biopsy that indicated CIN/VAIN2þ. The difference between the 2 groups was significant (P ¼.003; odds ratio [OR], 3.10; 95% confidence interval [CI], ) (Table 3). In the LSIL group, 13 of 29 women (45%) with HPV16/18 underwent a follow-up biopsy that indicated CIN/ VAIN2þ, whereas 17 of 59 women (29%) who had non- 16/18 HPV types underwent a follow-up biopsy that indicated CIN/VAIN2þ. The difference between the 2 groups was not statistically significant (P ¼.16; OR, 1.96; 95% confidence interval, ) (Table 4). In 10 women who had residual or recurrent CIN/VAIN2þ, 6 women had HPV16/18, and 4 had non-16/18 HPV types. DISCUSSION In the current study, we evaluated risk profiling among women who had mildly abnormal Pap results with or without positive HPV16/18 results by comparing the results from HPV genotyping tests with biopsy follow-up results. We observed that women with ASCUS and positive HPV16/18 test results had a significantly higher risk of having CIN/VAIN2þ lesions than those who had 82 Cancer Cytopathology February 2013
5 HPV16/18 in ASCUS and LSIL/Guo et al TABLE 4. Human Papillomavirus Genotypes and Follow-Up Biopsies in Women With Low-Grade Squamous Intraepithelial Lesion HPV Type No./Total With CIN/VAIN21 (%) P OR 95% CI HPV16/18 13/29 (45) Non-16/18 HPV 17/59 (29) 1.00 Abbreviations: CI, confidence interval; CIN/VAIN2þ, high-grade (grade >2) cervical neoplasm/vaginal intraepithelial neoplasm and carcinoma; HPV, human papillomavirus; OR, odds ratio. positive, non-16/18 HPV test results. Thus, we demonstrated that HPV16/18 genotyping may be used for risk assessment among women who have ASCUS Pap results and positive HPV DNA results. However, further studies with larger patients numbers and commercial HPV genotyping assays will be required to verify the clinical utility of HPV16/18 genotyping for women with ASCUS. It is well documented that >60% of women who have CIN3 are positive for HPV16/ However, how to use HPV16/18 genotyping information for women who have ASCUS or LSIL Pap results has not been established. Zuna et al reported a significantly increased rate of HPV16/18 detection in Pap specimens from LSIL to high-grade squamous intraepithelial lesion/carcinoma, suggesting the potential of using HPV genotyping as a risk-profiling component in the evaluation of women who have abnormal Pap results. 13 In a screening population, Castle et al demonstrated that positive HPV16/18 results were equivalent to ASCUS or worse Pap results in terms of sensitivity for CIN3, indicating a remarkable risk associated with HPV16/18 for women aged 25 years. 14 Recently, the potential clinical use of HPV16/18 genotyping in women with ASCUS has been reported. In a screening population, Stoler et al demonstrated that women who had ASCUS Pap results and positive HPV16/18 results had a significantly greater risk of CIN2þ (24.4%) compared with women who were positive for pooled high-risk HPV types (14%). 7 Einstein et al reported a study using the Cervista HPV16/18 assay in women with ASCUS Pap results and demonstrated that women who had positive HPV16/18 results had 17.2 times the risk of CIN2þ compared with those who had negative high-risk HPV results; whereas women who had non-16/18 HPV types had only 4.0 times the risk of CIN2. 15 Similarly, in the current study, we demonstrated a significant difference in the correspondence of positive HPV16/18 and non-16/18 HPV results with CIN/ VAIN2þ biopsy results in women who had ASCUS Pap results. Our findings and the published data demonstrate that the risk of CIN/VAIN2þ in women who have ASCUS Pap results and positive HPV16/18 results is substantial enough to warrant close follow-up. The clinical implication for women with ASCUS results and positive HPV16/18 results is the higher risk level of CIN/ VAIN2þ during follow-up. With HPV16/18 genotyping information, women who have HPV16/18 can be advised of the potential risk, which should lead to increased patient compliance with follow-up. Information on HPV16/18 status also may help clinicians avoid excessive and unnecessary follow-up of women who have non-16/ 18 HPV results. During clinical data review for the current study, we observed that many women who had mildly abnormal Pap results and subsequent positive HPV16/18 results were lost to follow-up partially because of the lack of relevant risk information for these patients. Conversely, in women who had non-16/18 HPV results or even those who had low-risk HPV types identified, more frequent colposcopy with negative biopsies were performed, and some patients underwent more than 1 colposcopy and biopsy within a year. In our study, although there was a significantly high positive predictive value of 43% among women who had ASCUS and positive HPV16/18 results, a positive predictive value of 19% among women who had non-16/18 HPV results is high enough for triage to immediate colposcopy. Consequently, women with ASCUS/HPVpositive results, including those who have non-16/18 HPV genotypes, still need immediate colposcopy evaluation as recommended by the new guidelines for cervical cancer screening. 16 However, HPV16/18 genotyping information can be used to refine the patient follow-up for women who have ASCUS Pap results, ie, to increase patient compliance for follow-up in women who have ASCUS/HPV16/18 results and to avoid excessive follow-up in women who have ASCUS/non-16/18 HPV results. Recently FDAapproved HPV testing assays, such as Cervista HPV16/18 and the Cobas HPV Test for HPV16/18 genotyping (F. Hoffmann-La Roche Ltd., Basel, Switzerland) have provided useful tools for clinicians in this regard. In women who had positive HC2 results, we observed a small fraction of nonhigh-risk HPV types among women who had ASCUS (15%) or LSIL (17%) Cancer Cytopathology February
6 Pap results. These rates were comparable to those reported in a previously published study. 17 Further separating this small fraction of non-high-risk HPV types from high-risk HPV types may not be clinically significant, because the group includes those who have borderline high-risk HPV types, such as HPV66, HPV67, HPV70, HPV73, and HPV82, which reportedly have certain risks of CIN/ VAIN2þ. 18 Therefore, in our study, the non-high-risk HPV types were combined with non-16/18 high-risk HPV group as non-16/18 HPV types for data analysis. For women who have LSIL Pap results, patient management can be challenging, partially because of the relatively low positive predictive value for CIN2þ in this group. 2 Clinically, LSIL and ASCUS Pap results can occur alternatively in women who have multiple mildly abnormal Pap results during follow-ups. Therefore, a Pap classification of ASCUS or LSIL in the same patient during followup may have similar clinical implications. In our study, we observed that 37% of women who had ASCUS results and 33% of women who had LSIL results had HPV16/18 genotypes. The rate of HPV16/18 was comparable to the previously published rate. 19,20 Furthermore, the rates of CIN2þ in biopsies during follow-up also were comparable between women with ASCUS or LSIL results in the current study and in our previously reported study in a screening population. 21 According to the current recommendation, women who have LSIL Pap results should be referred for colposcopy and biopsy. HPV DNA testing is recommended only for women who have LSIL after a negative colposcopy and biopsy. 2 In our LSIL group, we observed a higher rate of CIN2þ among women who were positive for HPV16/18 compared with those who had non-16/18 HPV genotypes. However, no statistically significant difference was observed between the 2 groups, possibly because of the small sample size of our LSIL groups. Further studies with larger patient numbers will be required to verify whether HPV16/18 genotyping can be useful for risk assessment in women who have LSIL Pap results. The limitations of our study are the small patient numbers, the origin of the study cohort from a cancer center composed of a relatively older population, a frequent history of cervical dysplasia, and the use of a PCR-based HPV testing assay that is not an FDA-approved method. More studies with large patient numbers from different populations should be performed with the available FDA-approved genotyping assay to confirm the clinical utility of HPV16/18 testing in women with ASCUS or LSIL for risk assessment and to determine the proper follow-up strategy. FUNDING SOURCES This study was supported by a Cervical Cytology and HPV Partnership Investigator Award from the American Society of Cytopathology and an interim grant from The University of Texas MD Anderson Cancer Center to Dr. Guo. CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189: Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197: Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88: Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89: Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97: Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010;102: Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135: Wheeler CM, Hunt WC, Schiffman M, Castle PE. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194: Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287: Guo M, Lin CY, Gong Y, et al. Human papillomavirus genotyping for the 8 oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results. Mod Pathol. 2008;21: Lin CY, Chen HC, Lin RW, et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods. 2007;140: Marks MA, Castle PE, Schiffman M, Gravitt PE. Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol. 2012;50: Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST. Distribution of HPV genotypes in 282 women with cervical lesions: evidence for 3 categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol. 2007;20: Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus 84 Cancer Cytopathology February 2013
7 HPV16/18 in ASCUS and LSIL/Guo et al (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12: Einstein MH, Garcia FA, Mitchell AL, Day SP. Age-stratified performance of the Cervista HPV 16/18 genotyping test in women with ASC-US cytology. Cancer Epidemiol Biomarkers Prev. 2011; 20: Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137: Alameda F, Bellosillo B, Lloveras B, et al. PCR study of a series of ASCUS cases HPV-positive by HCII [published online ahead of print June 7, 2011]. Diagn Cytopathol Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. Human papillomavirus genotype specificity of Hybrid Capture 2. J Clin Microbiol. 2008;46: Chacon J, Sanz I, Rubio MD, et al. [Detection and genotyping of high-risk human papillomavirus in cervical specimens]. Enferm Infecc Microbiol Clin. 2007;25: Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prevent. 2005; 14: Guo M, Hu L, Martin L, Liu S, Baliga M, Hughson MD. Accuracy of liquid-based Pap tests: comparison of concurrent liquid-based tests and cervical biopsies on 782 women with previously abnormal Pap smears. Acta Cytol. 2005;49: Cancer Cytopathology February
The devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationThe ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population
Accepted: 6 March 2017 DOI: 10.1111/cyt.12440 ORIGINAL ARTICLE The ATHENA HPV study underrepresents other high-risk HPV genotypes when compared with a diverse New York City population G. Ramos Rivera a
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationNILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA
NILM Pap Slides From Women 30 Years of Age and Older With Positive High-Risk HPV DNA Focused Rescreening Prior to Report Issuance, An Enhanced Quality Control Measure Karen Cormier, CT(ASCP), 1 Michael
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationClinical Relevance of HPV Genotyping. A New Dimension In Human Papillomavirus Testing. w w w. a u t o g e n o m i c s. c o m
Clinical Relevance of HPV Genotyping A New Dimension In Human Papillomavirus Testing Human Papillomavirus: Incidence HPV prevalence was 26.8% for women in US aged 14 59 yrs 1 20 million Americans are currently
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationCME/SAM. High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up
Anatomic Pathology / HPV Testing in Negative Papanicolaou Tests High-Risk HPV Testing in Women 30 Years or Older With Negative Papanicolaou Tests Initial Clinical Experience With 18-Month Follow-up Michael
More informationAbsolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women
Absolute Risk of a Subsequent Abnormal Pap among Oncogenic Human Papillomavirus DNA-Positive, Cytologically Negative Women 2145 Philip E. Castle, Ph.D., M.P.H. 1 Sholom Wacholder, Ph.D. 1 Mark E. Sherman,
More informationDetecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationPhilip E. Castle, Diane Solomon, Mark Schiffman, Cosette M. Wheeler for the ALTS Group
ARTICLEARTICLESHuman Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities Philip E. Castle, Diane Solomon, Mark Schiffman,
More informationClinical Performance of Roche COBAS 4800 HPV Test
JCM Accepts, published online ahead of print on 9 April 2014 J. Clin. Microbiol. doi:10.1128/jcm.00883-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 3 4 5 6 Clinical
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationDisclosures & images
Cervical Cancer Screening: New Approaches Levi S. Downs, Jr., MD Disclosures & images During the previous 12 months, I have been a consultant for and received honoraria from Merck. Images are attributed
More informationOriginal Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD;
More informationCINtec PLUS and the Pap smear: a co-testing alternative
CINtec PLUS and the Pap smear: a co-testing alternative Rosemary Tambouret MD p16/ki67 (CINtec PLUS) and the Pap smear Rosemary Tambouret MD CINtec PLUS dual stain: p16 and Ki67 p16 is anti-proliferative
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationHe Said, She Said: HPV and the FDA. Audrey P Garrett, MD, MPH June 6, 2014
He Said, She Said: HPV and the FDA Audrey P Garrett, MD, MPH June 6, 2014 Disclosure Speaker for Merck Gardasil Speaker for Hologic Thin Prep and Cervista Cervical Cancer Screening: 21 st century Dr. Papanicolaou
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationPushing the Boundaries of the Lab Diagnosis in Asia
Pushing the Boundaries of the Lab Diagnosis in Asia Diana Lim MBBS, FRCPA, FRCPath (UK) Senior Consultant National University Health System and National University of Singapore Department of Pathology
More informationThe Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal Women Over a 10-Year Period
Published Online First on October 23, 2006 as 10.1158/0008-5472.CAN-06-1057 Research Article The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationVery Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests
292 Very Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests Chengquan Zhao, MD 1 Esther Elishaev, MD 1 Ke-Hai Yuan, PhD 2 Jing Yu, MD 1 R. Marshall
More informationCan human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
J Gynecol Oncol. 2016 Nov;27(6):e56 pissn 2005-0380 eissn 2005-0399 Original Article Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification? Yeoun Eun
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More information1/12/2016. I do not engage in any lucrative deals that require disclosure.
I do not engage in any lucrative deals that require disclosure. Sabrina Hofmeister, DO Assistant Professor Columbia St. Mary s Family Medicine Residency Program MCW Department of Family and Community Medicine
More informationComparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Ming Guo
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/comparing-liquid-based-cytology-methodsdetection-cervical-cancer-perspectives-dr-ming-guo/7469/
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationPerformance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 1071 1076 Vol. 49, No. 3 0095-1137/11/$12.00 doi:10.1128/jcm.01674-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationSafe, Confident, QIAsure
Safe, Confident, QIAsure A new cervical cancer screening test Sample to Insight QIAsure: A breakthrough solution in Women s Health We are at a turning point in the battle against cervical cancer. The global
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 13: , 2017
3032 Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet
More informationEvidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR
Evidence-based treatment of a positive HPV DNA test Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR HPV DNA testing Indications 1. Triage after cytology with ASCUS/LSIL
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationSouthern California CSU DNP Consortium
Southern California CSU DNP Consortium California State University, Fullerton California State University, Long Beach California State University, Los Angeles ESSENTIAL CHANGES TO THE MANAGEMENT OF ABNORMAL
More informationFocus. International #52. HPV infection in High-risk HPV and cervical cancer. HPV: Clinical aspects. Natural history of HPV infection
HPV infection in 2014 Papillomaviruses (HPV) are non-cultivable viruses with circular DNA. They can establish productive infections in the skin (warts) and in mucous membranes (genitals, larynx, etc.).
More informationMEDICAL POLICY. SUBJECT: CERVICAL CANCER SCREENING and HUMAN PAPILLOMA VIRUS (HPV) TESTING
MEDICAL POLICY SUBJECT: CERVICAL CANCER SCREENING PAGE: 1 OF: 12 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationCME/SAM. Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results
Anatomic Pathology / HPV-Negative ASC-H Follow-up Outcomes in a Large Cohort of Patients With Human Papillomavirus Negative ASC-H Cervical Screening Test Results David Cohen, MD, R. Marshall Austin, MD,
More informationAbstract. Human papillomavirus (HPV) DNA testing is cost-effective 1-3 (S. Kulasingam, PhD, et al, unpublished Atypical
Anatomic Pathology / HPV DNA DETECTION IN ALTS A Comparison of a Prototype PCR Assay and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus DNA in Women With Equivocal or Mildly Abnormal
More informationEmerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections Erik Munson Wheaton Franciscan Laboratory Marquette University Milwaukee, Wisconsin 1 OBJECTIVES I. Appreciate the changing epidemiology
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Practices of Participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006 Galen M. Eversole, MD; Ann T. Moriarty,
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationBiomarkers and HPV testing: The future of cervical screening
THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationSince the 1960s, colposcopy of the cervix with
Original Research Relevance of Random Biopsy at the Transformation Zone When Colposcopy Is Negative Warner K. Huh, MD, Mario Sideri, MD, Mark Stoler, MD, Guili Zhang, PhD, Robert Feldman, MD, and Catherine
More informationEmerging Challenges in Primary Care. Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing
Emerging Challenges in Primary Care Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner
More informationHuman Papillomaviruses: Biology and Laboratory Testing
For our patients and our population Human Papillomaviruses: Biology and Laboratory Testing Geoffrey Higgins Microbiology and Infectious Diseases For our patients and our population HPV Associated Cancers
More informationAgreement Between Cytotechnologists and Cytopathologists as a New Measure of Cytopathologist Performance in Gynecologic Cytology
Agreement Between Cytotechnologists and Cytopathologists as a New Measure of Cytopathologist Performance in Gynecologic Cytology Andrew M. Quinn, MD 1 ; Abu T. Minhajuddin, PhD 2 ; Linda S. Hynan, PhD
More informationHuman Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer
MAJOR ARTICLE Human Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer Cosette M. Wheeler, 1,2 William C. Hunt, 1 Mark Schiffman, 3 and Philip E. Castle, 3 for the Atypical Squamous
More informationHierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study
Published OnlineFirst on October 19, 2010 as 10.1158/0008-5472.CAN-10-1188 Prevention and Epidemiology Hierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More informationComparison of Human Papillomavirus Distribution in Cytologic Subgroups of Low-Grade Squamous Intraepithelial Lesion
288 Comparison of Human Papillomavirus Distribution in Cytologic Subgroups of Low-Grade Squamous Intraepithelial Lesion Rosemary E. Zuna, MD 1 Sophia S. Wang, PhD 2 Mark Schiffman, MD, MPH 2 Diane Solomon,
More informationPOET REPORT Perspectives on Emerging Technology
POET REPORT Perspectives on Emerging Technology Testing for High-Risk Human Papillomavirus (hrhpv) DNA in the Management of Cervical Cancer October, 2010 Developed by the CAP s Technology Assessment Committee
More informationOriginal Articles. Squamous Cell Carcinoma of the Cervix. A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice
Original Articles Squamous Cell Carcinoma of the Cervix A Cytology-Histology-Human Papillomavirus Correlation in Clinical Practice Ross A. Miller, MD; Lindsay L. Waters, MD; Dina R. Mody, MD; Kimberlee
More informationHuman Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of
JCM Accepts, published online ahead of print on 1 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.06656-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 Human Papillomavirus
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study Citation for published version: Cuschieri, K, Cubie, H,
More informationRESEARCH. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
Short term of human papillomavirus and risk of cervical precancer and cancer: population based cohort study Philip E Castle, investigator, 1 Ana Cecilia Rodríguez, medical epidemiologist, 3 Robert D Burk,
More informationOBJECTIVES. Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections OBJECTIVES I. Appreciate the changing epidemiology of trichomoniasis and clinician ordering patterns on the basis of improved
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationCervical cancer screening in vaccinated population
Cervical cancer screening in vaccinated population Cytology and molecular testing Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol Izmir, November
More informationCervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
More informationBeyond Pap Morphological Triage: p16/ki67 Dual Staining
Moving away from Beyond Pap Morphological Triage: p16/ki67 Dual Staining Nicolas Wentzensen MD, PhD, MS Deputy Chief, Clinical Genetics Branch; Head, Clinical Epidemiology Unit National Cancer Institute
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationUsefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy
Usefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy Jaume Ordi, MD, PhD 1 ; Amaia Sagasta, MD 1 ; Meritxell Munmany, MD 2 ; Leonardo Rodrıguez-Carunchio, MD 1 ; Aureli Torne,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More information